Roche could this week learn whether the European Medicines Agency will recommend pan-EU marketing approval for mosunetuzumab, the company’s CD20xCD3 T-cell engaging bispecific antibody for treating refractory follicular lymphoma.
If Roche gets the thumbs up, it could become the first company to market a CD20xCD3 bispecific for follicular lymphoma,...